<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305186</url>
  </required_header>
  <id_info>
    <org_study_id>17801</org_study_id>
    <nct_id>NCT02305186</nct_id>
  </id_info>
  <brief_title>Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer</brief_title>
  <acronym>UVA-PC-PD101</acronym>
  <official_title>A Randomized Multicenter Ib/II Study to Assess the Safety &amp; Immunological Effect of Chemoradiation Therapy in Combination With Pembrolizumab Compared to CRT Alone Resectable/Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study an experimental drug called pembrolizumab or&#xD;
      MK-3475 for use in combination with chemotherapy and radiation therapy for patients with&#xD;
      resectable (surgical removal) or borderline resectable pancreatic cancer. In general,&#xD;
      pancreatic cancer that cannot be removed by surgery is sometimes treated with chemotherapy&#xD;
      and radiation therapy, called neoadjuvant treatment, to shrink the tumor so that surgery&#xD;
      might be possible. However, this is not always effective at shrinking the tumor enough to&#xD;
      allow it to be removed with surgery. Recent discoveries suggest that the investigators own&#xD;
      immune system might have a role in controlling the growth of tumors. Drugs such as&#xD;
      pembrolizumab can stimulate the immune system against cancer. The purpose of this study is to&#xD;
      investigate whether pembrolizumab can be used safely during neoadjuvant treatment and can&#xD;
      improve the body's immune response against pancreatic cancer.&#xD;
&#xD;
      Pembrolizumab has been approved for treatment of patients with melanoma but has not been&#xD;
      proven to be safe or helpful in patients with pancreatic cancer and is not approved by the&#xD;
      U.S. Food and Drug Administration (FDA) for this purpose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Tumor Infiltrating Lymphocytes (TILs) per high powered field (hpf) in pancreatic tissue (resected tissue).</measure>
    <time_frame>2-3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>2-3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>2-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Neodjuvant CRT + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard neoadjuvant chemoradiation treatment (CRT) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment</description>
    <arm_group_label>Neodjuvant CRT + Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant Chemoradiation</intervention_name>
    <description>Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)</description>
    <arm_group_label>Neoadjuvant CRT</arm_group_label>
    <arm_group_label>Neodjuvant CRT + Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.&#xD;
&#xD;
          2. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             Performance Scale&#xD;
&#xD;
          3. Adequate organ function&#xD;
&#xD;
          4. In subjects requiring biliary decompression, metal stent or drainage using&#xD;
             percutaneous transhepatic cholangiogram (PTC) are allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunodeficiency or taking steroid or any other form of immunosuppressive therapy&#xD;
&#xD;
          2. Has a plastic biliary stent for decompression&#xD;
&#xD;
          3. Metastatic disease&#xD;
&#xD;
          4. Prior treatment for pancreatic cancer (other than 4-8 cycles of Folfirinox) or prior&#xD;
             treatment with radiation for other diagnoses to the expected pancreatic cancer&#xD;
             treatment area&#xD;
&#xD;
          5. Active autoimmune disease&#xD;
&#xD;
          6. Pregnancy or Nursing&#xD;
&#xD;
          7. Known history of Human Immunodeficiency Virus (HIV) or Hepatitis B or C&#xD;
&#xD;
          8. Prior monoclonal antibody within 4 weeks prior to study Day 1&#xD;
&#xD;
          9. Known additional malignancy that is progressing or requires active treatment&#xD;
&#xD;
         10. Evidence of interstitial lung disease or active, non-infectious pneumonitis&#xD;
&#xD;
         11. Active infection requiring systemic therapy&#xD;
&#xD;
         12. Prior therapy with an anti-Program Death (PD-1) antibody, anti-PD-L1, anti-PD-L2, or&#xD;
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Rahma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Alicea</last_name>
    <phone>434-243-5350</phone>
    <email>xzy7tw@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katie Rea</last_name>
    <phone>434-924-8574</phone>
    <email>kaw3j@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Weber</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <contact_backup>
      <email>weber.justin@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chee-Chee Stucky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford HealthCare</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Persky</last_name>
      <email>leah.persky@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Rawad Elias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Metayer</last_name>
      <phone>617-632-6316</phone>
      <email>KatherineA_Metayer@DFCI.HARVARD.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Osama Rahma, MD</last_name>
      <email>OsamaE_Rahma@DFCI.HARVARD.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Osama Rahma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edsel Esquivel</last_name>
      <email>EFEsquivel@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauri Varadhachary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Mahmutovic</last_name>
      <email>am6bd@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Director of the UVA Human Immune Therapy Center</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Resectable</keyword>
  <keyword>Borderline resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

